Oral mucositis is the most common complication of chemotherapy in cancer patients. It causes damage to mucosal lining of the mouth which results in formation of ulcers. It can result in several problems that includes severe pain in mouth, nutritional problems as a result of inability to eat and increased risk of infection due to open sores in the mucosa.
The study analyzed that the oral mucositis therapeutics pipeline comprises approximately 18 drug candidates in different stages of development.
Access Report Overview: www.psmarketresearch.com/market-an…ipeline-analysis
Oragenics, Inc. is using ActoBiotics technology platform for the development of their drug candidates for the treatment of oral mucositis. The technology platform produces a new class of orally delivered biopharmaceuticals.
Through ActoBiotics technology platform, food-grade microbes are engineered to generate biologically contained ActoBiotics therapeutics for in situ expression and secretion of novel proteins and peptides including cytokines, enzymes, hormones and monoclonal antibodies within the body.
Explore Report Sample at: www.psmarketresearch.com/market-an…is/report-sample
Some of the other key players developing drugs for the treatment of oral mucositis include Daewoong Pharmaceutical Co., Ltd., Cellceutix Corporation, Soligenix, Inc. and others.
Category: Market Research Publishers and RetailersCompany profile: PS Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries. With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our pub ...
For more information: